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Introduction
Thyroid hormone receptor interactor 11 (TRIP11, also known as Golgi-associated microtubule-binding 
protein 210 [GMAP-210], MIM 604505) is essential for normal skeletal development and endochondral 
ossification. Previously, recessive loss-of-function mutations of  the TRIP11 gene were found to cause 
achondrogenesis type 1A (ACG1A, MIM 200600) (1), a severe chondrodysplasia characterized by short 
trunk, narrow chest, short extremities, and craniofacial malformations (2, 3). In the majority of  cases, ante-
natal suspicion of  a lethal chondrodysplasia based on sonographic findings leads to an early termination of  
pregnancy (4). In ACG1A fetuses who are carried to full term, thoracic hypoplasia and rib fractures lead to 
respiratory insufficiency and perinatal death (3). Respiratory failure and perinatal death were also observed 
Odontochondrodysplasia (ODCD) is an unresolved genetic disorder of skeletal and dental 
development. Here, we show that ODCD is caused by hypomorphic TRIP11 mutations, and we 
identify ODCD as the nonlethal counterpart to achondrogenesis 1A (ACG1A), the known null 
phenotype in humans. TRIP11 encodes Golgi-associated microtubule-binding protein 210 (GMAP-
210), an essential tether protein of the Golgi apparatus that physically interacts with intraflagellar 
transport 20 (IFT20), a component of the ciliary intraflagellar transport complex B. This association 
and extraskeletal disease manifestations in ODCD point to a cilium-dependent pathogenesis. 
However, our functional studies in patient-derived primary cells clearly support a Golgi-based 
disease mechanism. In spite of reduced abundance, residual GMAP variants maintain partial Golgi 
integrity, normal global protein secretion, and subcellular distribution of IFT20 in ODCD. These 
functions are lost when GMAP-210 is completely abrogated in ACG1A. However, a similar defect in 
chondrocyte maturation is observed in both disorders, which produces a cellular achondrogenesis 
phenotype of different severity, ensuing from aberrant glycan processing and impaired extracellular 
matrix proteoglycan secretion by the Golgi apparatus.
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in mice with a homozygous-targeted deletion of  Trip11 (1, 5, 6). Lethality in mice may, however, may also 
be due to primary pulmonary pathology rather than a small rib cage, which is considered the critical prob-
lem in humans (5). Characterization of  the skeletal phenotype and functional studies in mice suggested 
that the pathogenesis of  ACG1A may be explained by the known intracellular function of  GMAP-210 as 
a Golgi-associated vesicle tethering protein (1, 6–8). Conversely, GMAP-210 interacts with intraflagellar 
transport 20 (IFT20) that is involved in ciliary trafficking processes and phenotypic features in both mice 
and humans, such as thoracic dystrophy, pulmonary dysplasia, and hydrocephaly, suggesting that develop-
mental defects in ACG1A may also be due to impaired ciliary functions (5, 9).
Odontochondrodysplasia (ODCD, MIM 184260) is an unresolved skeletal dysplasia recognized as a 
distinct entity by Goldblatt et al. in 1991 (10). Key clinical findings are short stature, narrow chest, mesome-
lic limb shortening, brachydactyly, joint laxity, and dental anomalies (11). Radiographic features include 
platyspondyly with coronal clefts and metaphyseal irregularities of  the tubular bones (12).
We here unravel the molecular basis of  ODCD and describe a genotype-phenotype correlation, rang-
ing from ACG1A as the null phenotype to ODCD caused by recurrent hypomorphic TRIP11 mutations. 
Detailed analyses of  TRIP11-mutant primary cells revealed that Golgi organization, global secretory capac-
ity, and IFT20 Golgi targeting are preserved in ODCD but are lost in ACG1A. However, in both mild and 
severe disease, mutations of  TRIP11 impair Golgi glycan processing and synthesis of  glycosylated cartilage 
matrix proteins, specifically disrupting hypertrophic chondrocyte differentiation in skeletal development.
Results
The clinical presentation of  ODCD is variable and includes renal and cerebral anomalies. To unravel the genetic 
basis of  ODCD, we ascertained a series of  10 patients from 7 unrelated families; cases 1–6 were published 
previously (Table 1, patient and family numbering corresponds to the report of  Unger et al., 2008; ref. 
12). All additional index cases met the clinical and radiographic criteria defined earlier (11, 12). Clinical 
follow-up of  the published and new families further contributed important information (Table 1). First, 
pedigrees supported recessive inheritance (Supplemental Figure 1; supplemental material available online 
with this article; https://doi.org/10.1172/jci.insight.124701DS1). Second, additional extraskeletal disease 
manifestations of  ODCD included pulmonary dysplasia, cystic renal disease, and nonobstructive hydro-
cephaly. Third, it became evident that disease manifestations may range from early lethal to long-term 
survival with short stature (Table 1).
Table 1. Clinical summary of the 10 odontochondrodysplasia cases
Case Family Sex Manifestation Outcome Skeletal disease Extraskeletal disease Reference
1
1
Male Severe Death at 4m Td, SMD, Mm, Bd, 
Mc, Ss
Pulmonary hypoplasia
12
2 Female Mild Alive at 16y Td, SMD, Sc, Ms, Bd, 
Mc, Ss
DI
3 2 Female Mild Alive at 17y Td, SMD, Sc, Ms, Bd, 
Mc, Ss
DI 12
4 3 Female Mild Alive at 30y SMD, Sc, Ms, Bd, 
Mc, Ss
DI 12
5 4 Female Mild Alive at 17y Td, SMD, Ms, Bd, 
Mc, Ss
DI 12
6 5 Male Severe Alive at 12y Td, SMD, Sc, Pc, Ms, 
Bd, Mc, Ss
DI, hydrocephaly, polycystic 
kidneys
12
7 6 Female Mild Alive at 16y Td, SMD, Sc, Pc, Ms, 
Bd, Mc, Ss
DI, recurrent respiratory 
infections
Current study
8
7
Male Severe Death at 3m Td, SMD, Ms, Bd, 
Mc, Ss
Pulmonary hypoplasia, 
nephronophthisis
Current study9 Male Severe Death at 6m Td, SMD, Ms, Bd, 
Mc, Ss
DI, Pulmonary hypoplasia
10 Female Mild Abortion at 22w Td, SMD, Bd, Mc Pulmonary hypoplasia
Td, thoracic dystrophy; SMD, spondylometaphyseal dysplasia; Mm, micromelia; Bd, brachydacyly; Mc, macrocephaly; Ms, mesomelic shortening; Pc, pectus 
carinatum; Sc, scoliosis; Ss, short stature; y, years;, d, days; m, months; w, weeks; DI, dentinogenesis imperfecta.
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On review of  the early radiographic presentation of  ODCD, we realized close similarities between 
ACG1A and severe ODCD (Figure 1). In both disorders, there was intra- and interfamilial clinical and 
radiographic variability (13). Furthermore, some alterations such as short, plump tubular bones with 
cupped metaphyses flanked by longitudinal spurs, short ribs, and a trident pelvis supported the assumption 
of  a skeletal ciliopathy (14). We therefore screened for ciliopathic disease manifestations in ODCD. Clin-
ical characteristics of  ciliopathies, such as renal congenital hypodysplasia, childhood-onset cystic kidney 
degeneration and relative macrocephaly, were found in a few patients (Table 1) (14), in support of  a pos-
sibly cilium-based pathophysiology (15). An important consequence of  our observations for the clinical 
management of  ODCD is the need for regular screening, including neuroimaging and ophthalmoscopy, to 
prevent secondary complications from hydrocephaly and unrecognized renal failure.
Splice mutations of  TRIP11 cause ODCD. The underlying genetic defect of  ACG1A has been identified 
as recessive loss-of-function of  the TRIP11 gene (1), which encodes GMAP-210 (16, 17). The phenotypic 
similarities prompted us to perform direct mutation analysis of  TRIP11 in ODCD. In all affected individuals, 
Sanger sequencing revealed biallelic changes that cosegregated with the disease phenotype (Figure 2A, Sup-
plemental Figure 1, and Table 2). Parents were heterozygous; unaffected siblings were heterozygous or WT. 
None of  the changes were known polymorphisms or were listed in public exome databases. As in ACG1A, 
ODCD-associated TRIP11 mutations were scattered over the whole gene (Figure 2A). At first glance, the 
mutational spectrum of TRIP11 in ODCD was similar to ACG1A, comprising predominantly small deletions 
Figure 1. Clinical and radiographic spectrum of TRIP11-related disorders. (A–D) Odontochondrodysplasia, case 6 at age 2 years; radiographs were 
obtained at the age of 3 years. (E–H) Mild achondrogenesis 1A (ACG1A); case A3 at day 3 of life. (I–L) Severe ACG1A; case A5 at 22 weeks of gestation. (B, 
F, and J) Radiographs demonstrate thoracic dystrophy of increasing severity; horizontally oriented short ribs have splayed ends. Vertebral bodies are flat, 
clefted, and under-ossified. (C, G, and K) Iliac bones are hypoplastic; ossification of ischial and pubic bones is strongly retarded or absent. Tubular bones 
are extremely short and bowed with metaphyseal cupping. (D, H, and L) Severe brachydactyly of metacarpals and phalanges, which show metaphyseal 
cupping and bilateral spurs of cortical bone extending longitudinally.
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and point mutations (Figure 2A, Table 2, and Supplemental Table 1). These cause a frameshift and/or a 
premature stop codon in the TRIP11 open reading frame (ORF) and, thus, predict a complete loss of  protein 
function. One of  the stop mutations in ODCD was recurrent and previously reported in ACG1A (c.790C>T) 
(1, 13). However, only in ODCD patients, compound heterozygous mutations were detected, which pre-
dict amino acid substitutions of  the GMAP-210 protein (p.Asp410Tyr, p.Met1806Val). Furthermore, a splice 
mutation was found in family 1 (c.1314+5G>A, Table 2). As altered splicing may vary in different cell types 
and may not be fully penetrant, we hypothesized that ODCD-associated TRIP11 mutations were less damag-
ing at the molecular level.
For 4 ODCD patients and 2 ACG1A fetuses, about whom findings have been previously published 
(1), materials were available to investigate the consequences of  individual mutations in detail (Table 3). 
As expected, mutations that introduce translational termination codons had the same effect on TRIP11 
mRNA, which was reduced to very low levels in both ACG1A and ODCD patients, most likely due to 
nonsense-mediated mRNA decay (NMD) (Figure 2, B and C, and Table 3) (18).
The recurrent c.586C>T transition, detected in 3 ODCD families, was also expected to cause NMD 
due to an early GMAP-210 truncation (p.Gln196*). However, we were surprised to find that the muta-
tion, instead, abrogates a splice donor site, causing complete in-frame skipping of  exon 4 (TRIP11-ΔEx4) 
Figure 2. Recessive mutations in TRIP11 cause achondrogenesis type 1A (ACG1A) and odontochondrodysplasia (ODCD). 
(A) Diagram of the human TRIP11 locus and relative size of its 21 coding exons. Lines indicate mutations identified in 
ACG1A (top) and ODCD (bottom) pointing to their locations within the exons. Nonsense and frameshift mutations are 
depicted in black, splice mutations in blue, and mutations shared by ODCD and ACG1A in red; recurrent mutations are 
underlined. (B) Semiquantitative reverse transcription PCR of TRIP11 using cDNA of control fibroblasts (CTL1 to -4), 
fibroblasts of ACG1A cases A1 and A2, and ODCD cases 6, 3, and 10. TBP was used for normalization. (C) Quantitative PCR 
(qPCR) analysis of TRIP11 using cDNA derived from control and patients’ fibroblasts. TBP and HPRT were used for nor-
malization. For qPCR results, the average value of the controls (n = 12) was set to 1. For TRIP11-mutant cells, horizontal 
lines represent the mean of quadruplicates (n = 4); error bars indicate SD. Statistical differences were assessed by 2-way 
ANOVA with Bonferroni’s post hoc test; ****P < 0.0001. –RT, without reverse transcriptase.
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in fibroblasts (case 10; Figure 3, A and D, and Supplemental Figure 2A). We therefore systematically 
analyzed all ODCD-associated mutations for a potential effect on splicing. Both predicted missense vari-
ants caused aberrant splicing, as well (Figure 3, B–D, and Supplemental Figure 2, B and C). They led 
either to in-frame skipping of  exon 9 (case 3, TRIP11-ΔEx9) or to an exonic missplice of  exon 18 (case 6). 
However, quantitative sequence analysis of  exon-spanning cDNA amplicons in case 6 also revealed the 
c.5416A>G transition encoding the conservative p.Met1806Val substitution in 56% of  transcripts (Sup-
plemental Figure 3, A and B). Furthermore, while TRIP11-ΔEx9 including the complete 5′-end was the 
predominant transcript in case 3 (Supplemental Figure 3C), exon 9–containing mRNA was also found, 
which indicates that aberrant splicing was not fully penetrant for all mutations (Supplemental Figure 
3D). The effect of  splice mutations was cell type dependent, as demonstrated by a different splicing pat-
tern in leukocytes (Supplemental Figure 4).
Taken together, the experimental evidence shows aberrant splicing of  TRIP11 in all ODCD cases inves-
tigated (Table 3). Due to recurrence of  splice mutations, potentially functional GMAP proteins were pre-
dicted in all patients that are identical to, or overlapping with, natural isoforms (Figure 3D). Since splicing 
of  TRIP11 was cell type dependent and not fully penetrant, we assumed that transcripts in some tissues 
are occasionally spliced correctly and that residual missense or WT GMAP-210 protein may influence the 
overall phenotypic outcome.
TRIP11 is alternatively spliced in chondrogenic differentiation. The occurrence of  in-frame TRIP11 vari-
ants in ODCD is intriguing, since — similar to TRIP11-ΔEx4 (19) — transcripts lacking exon 9 and car-
rying a shorter 5′-end also exist in healthy individuals (TRIP11-ΔEx9short; Figure 3D). The cDNA of  
this natural isoform predicts a 190 kDa GMAP protein lacking the amino-terminus, which encompasses 
the amphipathic lipid-packing sensor (ALPS) motif  essential for vesicle tethering (7, 20) and a recently 
Table 2. TRIP11 mutations in the 7 odontochondrodysplasia-affected families
Case Family Origin Consanguinity Nucleotide changes Status Location Predicted amino 
acid changes
Amino acid changes 
based on cDNA 
sequence
Mutational 
effect in 
primary cells
1
1 Maroccan (?)
c.[1314+5G>A]; [chr14:g.  
(?_ 92.474.069)_ 
(92.597.431_?)del
Compound 
heterozygous
Int10
p.[(Glu439Valfs*20)]; 
[(?)]A
n.a. n.a.
2
3 2 Turkish No c.[1228G>T]; 
[4815_4818delAGAG]
Compound 
heterozygous
Ex9; 
Ex1-10; 
Ex13
p.[(Asp410Tyr)]; 
[(Glu1606Leufs*3)]
p.[Asp410_
Lys438del]; 
[Glu1606Leufs*3]
Missplice/
frameshift, 
loss of TRIP11 
mRNA and 
protein
4 3 English No c.[586C>T];[4534C>T] Compound 
heterozygous
Ex4; 
Ex11
p.[(Gln196*)]; 
[(Gln1512*)]
n.a. n.a.
5 4 Turkish No c.[1228G>T]; 
[2128_2129delAT]
Compound 
heterozygous
Ex9; 
Ex11
p.[(Asp410Tyr)]; 
[(Ile710Cysfs*19)] 
p.[Asp410Glyfs*12]; 
[Ile710Cysfs*19]
Missplice/
frameshift, 
loss of TRIP11 
mRNA and 
protein
6 5 German No c.[1622delA]; [5416A>G] Compound 
heterozygous
Ex11; 
Ex18
p.[Lys541Argfs*17]; 
[(Met1806Val)] 
p.[(Lys541Argfs*17)]; 
[Met1806Val] 
[Leu1805Cysfs*13]
Missplice/
frameshift, 
loss of TRIP11 
mRNA and 
protein/
missense
7 6 Argentinian No c.[586C>T]; 
[2993_2994delAA]
Compound 
heterozygous
Ex4; 
Ex11
p.[(Gln196*)]; 
[(Lys998Serfs*5)]
n.a. n.a.
8
7 Thai No c.[586C>T]; [790C>T]
Compound 
heterozygous
Ex4; 
Ex5
p.[(Gln196*)]; 
[(Arg264*)]
p.[Val105_
Gln196del]; 
[Arg264*]
Missplice, 
loss of TRIP11 
mRNA and 
protein/ 
truncation
9
10
ALarge genomic deletion affecting exons 1–10.
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described second vesicle tethering motif  (21). Public transcriptome data suggest that TRIP11-ΔEx9short 
is transcribed in chondrocytes and osteoblasts (22, 23). We therefore performed exon-spanning reverse 
transcription PCR (RT-PCR) analysis of  human chondrogenic cells derived from primary fibroblasts by 
reprogramming (24, 25). While the TRIP11-ΔEx4 transcript was not detectable, TRIP11-ΔEx9short and 
full-length mRNA were highly expressed (Supplemental Figure 5A). The abundance of  both isoforms 
increased continuously during chondrogenic differentiation and was highest when cells reached the 
stage of  hypertrophy (Supplemental Figure 5A). The same distribution of  TRIP11 mRNA isoforms was 
found in primary human articular chondrocytes from healthy donors (Supplemental Figure 5B).
In addition to an intense signal at 230 kDa representing the full-length GMAP-210 protein, a number 
of  smaller GMAP proteins were detected in chondrogenic cells by using a carboxy-terminal antibody, 
including approximately 30 kDa lower bands present in WT fibroblast-derived chondrocytes (FDCs) 
(Supplemental Figure 5C). This GMAP variant, with a calculated molecular weight of  190 kDa, runs 
at approximately 210 kDa and may represent the translation product of  TRIP11-ΔEx9short. In accor-
dance with RNA analysis, both GMAP-190 and GMAP-210 proteins were induced upon chondrogenic 
differentiation (Supplemental Figure 5C). Thus, specific mRNA and corresponding protein isoforms are 
potentially relevant for endochondral ossification and skeletal development. Assuming that disease-as-
sociated and/or natural GMAP proteins may rescue embryonic lethality in ODCD, we investigated the 
functioning of  these GMAP variants in detail.
Shorter GMAP proteins are produced at low levels in ODCD. All disease-associated mutations in TRIP11 
are predicted to alter the primary structure of  the GMAP-210 protein (Figure 4A) and caused a strong 
reduction of  GMAP-210 abundance in patient-derived primary cells (Figure 4B). However, longer expo-
sure revealed weak signals at expected sizes for the respective variants in all ODCD cases, whereas 
GMAP-specific bands remained at or below the detection limit in ACG1A, indicating near-complete loss 
of  the protein (Figure 4, B–E).
Case 10 carries the most prevalent splice mutation affecting exon 4 and a null allele (Table 2 and Table 3). We 
expected a GMAP protein of approximately 10 kDa lower molecular weight, since exon 4 codes for 92 amino 
acids of the coiled coil sequence (Figure 4A). Accordingly, a single lower band was found in patient-derived fibro-
blasts using antibodies directed against the amino-terminus of GMAP-210 (Figure 4, B and D). The identified 
GMAP protein corresponds to TRIP11-ΔEx4 and is identical to a GMAP-200 isoform previously characterized in 
HeLa cells (19). Quantitative analysis indicated that GMAP-200 protein levels in case 10 only amount to approx-
imately 30% compared with full-length GMAP-210 in WT controls (Figure 4C).
Table 3. TRIP11 mutations in primary cells
Case Cell type Nucleotide changes Status Location Amino acid changes based 
on cDNA sequence
Mutational effect in 
primary cell
3 Fibroblasts c.[1228G>T]; [4815_4818delAGAG] 
Compound 
heterozygous Ex9; Ex13
p.[Asp410_Lys438del]; 
[Glu1606Leufs*3]
Missplice/in-frame 
exon 9 variants
Frameshift/NMD
5 Leukocytes c.[1228G>T]; [2128_2129delAT]
Compound 
heterozygous Ex9; Ex11
p.[Asp410Glyfs*12]; 
[Ile710Cysfs*19]
Missplice/frameshift/
NMD
Frameshift/NMD
6 Fibroblasts c.[1622delA]; [5416A>G] Compound heterozygous
Ex11;
Ex18
p.[Lys541Argfs*17];
[Met1806Val] and 
[Leu1805Cysfs*13]
Frameshift/NMD
Missense
Missplice/frameshift/
NMD
10 Fibroblasts c.[586C>T]; [790C>T] Compound heterozygous Ex4; Ex5
p.[Val105_Gln196del]; 
[Arg264*]
Missplice/in-frame 
exon 4 variant
NMD
A1 Fibroblasts c.[3478C>T]; [3499C>T] Compound heterozygous Ex11 p.[Gln1160*]; [Arg1167*]
NMD
NMD
A2 Fibroblasts c.[3671G>A]; [3671G>A] Homozygous Ex11 p.[Trp1224*]; [Trp1224*]
NMD
NMD
NMD, nonsense-mediated mRNA degredation.
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In case 3, we expected a GMAP protein missing the 29 amino acids encoded by exon 9 (Table 2, Table 
3, and Figure 4A). Accordingly, Western blot demonstrated a 3-kDa lower GMAP-207 protein in fibro-
blasts corresponding to TRIP11-ΔEx9 (Figure 4, B, D, and E) bearing the exon 9 missplice and a compound 
TRIP11 nonsense mutation (Table 2 and Table 3). Using amino- and carboxy-terminal antibodies, only a 
faint single band was visible with an abundance of  less than 10% as compared with the mean signal of  
full-length protein in healthy controls (Figure 4C). As the corresponding TRIP11-ΔEx9 mRNA was not 
decreased below the level of  haplo-insufficiency (Figure 2C), we concluded that the GMAP-207 protein 
variant was either less efficiently translated or less stable than the full-length GMAP-210.
In case 6, bearing the c.5416A>G splice/missense mutation and an early truncating mutation on 
the other allele predicting NMD (p.Lys541Argfs*17), we expected a full-length missense GMAP-210 
protein of  low abundance, as more than half  of  the remaining TRIP11 transcripts encoded the p.Met-
1806Val amino acid substitution (Figure 4A, Supplemental Figure 3B) and the concentration of  total 
TRIP11 mRNA was strongly reduced (Figure 2C). Accordingly, we only detected trace amounts of  
a protein with the same electrophoretic mobility as WT GMAP-210 (Figure 4, B, D, and E). Thus, 
endogenous and disease-associated splice variants of  TRIP11 were translated in all ODCD cases ana-
lyzed. To determine if  the resulting marginal amounts of  shorter GMAP proteins were sufficient to 
rescue the cellular consequences of  GMAP-210 deficiency (1, 20, 26), we characterized the residual 
protein function in detail.
Figure 3. Aberrant splicing of TRIP11 in odontochondrodysplasia. (A–C) Exon-spanning reverse transcription PCR (RT-PCR) analysis of TRIP11 using 
cDNA derived from patient and control (CTL) fibroblasts; amplicons resulting from aberrantly spliced mRNA are marked by red arrowheads. (A) The 
c.586C>T TRIP11 mutation causes in-frame skipping of exon 4, as indicated by the reduced PCR product size of 229 bp in case 10. (B) The recurrent 
c.1228G>T mutation causes in-frame deletion of exon 9, as indicated by the 87-bp shorter PCR product in case 3. (C) The c.5416A>G mutation gener-
ates an ectopic splice donor site within exon 18, as indicated by a 46-bp shorter PCR product in case 6. In addition, a PCR product of similar intensity 
indicating regular splicing is visible at 475 bp. (D) Schematic representation of TRIP11 transcript variants including their 5′ and 3′ untranslated region 
detected in control (CTL) and patient fibroblasts (cases 10, 3, and 6). Exons 1–21 are shown as boxes, the size of the box correlates to the size of each 
exon; introns represented as lines are not to scale. Triangular-shaped lines above indicate splicing. Gray horizontal arrows indicate the relative position 
of primers (E1, E5, E7, E10, E11, E14, and E19) used in this study. Red vertical arrows indicate mutations. FL, full-length transcript. Amphipathic lipid 
sensor (ALPS) in red, which participates in vesicle tethering with an overlapping second motif (not shown); Rab-binding domains 1 and 2 (RBD1 and 
RBD2) in light gray, which mediate RAB2 binding; and the GRIP-related Arf-binding (GRAB) domain in blue, which mediates membrane anchoring of 
GMAP. The IFT20 binding site (IFT20 BS) in black is necessary for Golgi targeting of IFT20.
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Figure 4. GMAP-210 protein analysis in achondrogenesis 1A (ACG1A) and odontochondrodysplasia (ODCD) 
patient–derived primary cells. (A) Schematic of the 1,979 amino acid GMAP-210 protein. The backbone of coiled-
coil domains is shown in gray; the amphipathic lipid sensor (ALPS) in red, which participates in vesicle tethering 
with an overlapping second motif (not shown); Rab-binding domains 1 and 2 (RBD1 and RBD2) in light gray, which 
mediate RAB2 binding; and the GRIP-related Arf-binding (GRAB) domain in blue, which mediates membrane 
anchoring of GMAP. The IFT20 binding site (IFT20 BS, in black) is necessary for Golgi targeting of IFT20. Mutations 
identified in 5 ACG1A and 10 ODCD cases are indicated below; those amenable to functional analysis are indicated 
above. Amino acids deleted by in-frame exon skipping are hatched; nonsense and frameshift mutations are depict-
ed in black, splice mutations in blue, and mutations shared by ACG1A and ODCD in red; recurrent mutations are 
underlined. (B) GMAP proteins in whole-cell protein lysates of patients and controls; GAPDH staining demonstrates 
total protein loading. The mean of triplicate quantitative blot signal analyses is represented in C; error bars indi-
cate ± SEM. (D–E) GMAP-210 in whole-cell protein lysates of patients and controls using more sensitive enhanced 
chemiluminescence (ECL) substrate to analyze low-abundant GMAP protein variants with polyclonal antibodies 
directed against the N-terminus and the C-terminus. (D) Note the ~3 kDa lower protein variant in case 3 (consis-
tent with the loss of exon 9) and the ~10 kDa lower protein variant in case 10 (consistent with the loss of exon 4). 
Red asterisks mark specific signals in the ACG1A cases (consistent with biallelic stop mutations and a predicted 
protein size of about 142 kDa in case A2 and 134 kDa in case A1). Additional bands for GMAP-210 marked with blue 
asterisks in CTL cells may represent shorter variants or proteolytic cleavage products. (E) Green asterisks mark the 
putative GMAP-190 protein corresponding to TRIP11-ΔEx9short.
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Residual GMAP proteins are correctly anchored, but the Golgi structure is altered in ODCD. Recent studies have 
shown that GMAP-210 acts as a tether for transport vesicles at the cis-Golgi in human cells (7, 8, 20). There-
fore, we investigated the subcellular distribution and local abundance of disease-associated GMAP variants 
in patient-derived primary cells. Immunofluorescence microscopy revealed a strong signal for GMAP-210 
at the Golgi apparatus in controls, costaining with the cis-Golgi marker GM130 (Figure 5). In contrast, no 
GMAP-210–specific signal was detected in fibroblasts of ACG1A cases A1 and A2 bearing biallelic nonsense 
mutations in TRIP11. Remarkably, while GMAP-210 staining was less intense in ODCD than in controls, red-
green-blue (RGB) profile blots demonstrated that the residual protein was still correctly targeted to the cis-Golgi 
in each case (Figure 5). We further noted that there was compaction of the Golgi apparatus in ACG1A and in 
ODCD case 6, which had the lowest amount of residual GMAP protein. In contrast, a close-to-normal Golgi 
Figure 5. Residual GMAP protein 
variants are found at the cis-Golgi 
in odontochondrodysplasia (ODCD). 
Wide-field microscopy of control 
and patient-derived fibroblasts 
costained with carboxy-terminal 
GMAP-210 antibody and the cis-Gol-
gi marker GM130. Yellow and white 
arrows mark the cis-Golgi. Nuclear 
DNA was stained with Hoechst 
33342 dye. Note that the GMAP-210 
carboxy-terminal antibody gives 
a nuclear staining, in addition to 
detecting Golgi-associated GMAPs. 
The area selected for red-green-
blue (RGB) profiling is indicated by 
a white line. Fluorescence intensity 
is shown in RGB profile plots (right). 
G, Golgi apparatus. Scale bar: 10 μm.
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ribbon morphology was seen in case 10, where the strongest GMAP-specific signals were detected. These find-
ings were verified using Golgi subcompartment–specific antibodies (Supplemental Figure 6).
To confirm their ability to anchor to the cis-Golgi, GMAP variants lacking exons 4 and 9 were ana-
lyzed when overexpressed at higher levels in generic cell lines (Supplemental Figure 7A). No alteration 
was seen in subcellular localization of  overexpressed GMAP-200 (encoded by TRIP11-ΔEx4) and GMAP-
207 (encoded by TRIP11-ΔEx9); both proteins were anchored at the cis-Golgi as efficiently as full-length 
protein, which is via the conserved carboxy-terminal GRIP-related Arf-binding (GRAB) domain (Supple-
mental Figure 7B) (27). Therefore, neither the amino-terminus encoded by the exons 1–5, nor the domains 
encoded by exons 4 and 9 alone, were critical for the Golgi anchoring of  GMAP-210, which was expected 
from previous studies (27, 28).
Transmission electron microscopy (TEM) corroborated the critical structural function of GMAP-210 for the 
human Golgi apparatus, since the cisternal stack architecture was completely lost in ACG1A (29). Numerous 
large vesicular profiles accumulated in the Golgi region, and none of the analyzed GMAP-210–negative cells 
showed distinguishable Golgi ribbons (Figure 6A). In accordance with the immunofluorescence data (Figure 5 
and Supplemental Figure 6), ultrastructural abnormalities were considerably milder in ODCD. However, Golgi 
stacks in ODCD exhibited dilated cisternae, with accumulation of small and large vesicular profiles (Figure 6A), 
Figure 6. Golgi ultrastructure in achondrogenesis 1A (ACG1A) and odontochondrodysplasia (ODCD). (A) Transmission 
electron microscopy (TEM) of patient and control cells. Blue arrowheads mark normal Golgi stacks; red arrowheads 
mark Golgi mini stacks, while red asterisks depict Golgi vesiculation. Scale bar: 500 nm. (B) Quantification of cells with 
abnormal vesiculation, defined as peri-Golgi circular profiles with a diameter of >100 nm (n > 25). The number of cells 
with large vesicular profiles was compared using a χ2 test. Statistical significance cut-offs were set as follows: **P < 
0.01 and ***P < 0.001.
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likely corresponding to cisternal remnants and/or untethered transport vesicles (20). Quantification of the ultra-
structural disease phenotype revealed that Golgi vesiculation correlated negatively with the amount of GMAP 
proteins left in patients’ cells (Figure 6B). ER ultrastructure was unchanged in ACG1A and ODCD fibroblasts 
(Supplemental Figure 8), contrary to observations in Trip11-mutant mouse chondrocytes (1).
To assess the functional competence of  the individual GMAP variants, they were overexpressed in 
cells derived from an ACG1A case. ODCD-associated variants lacking exons 4 and 9, as expressed in 
cases 10 and 3, restored normal Golgi organization in GMAP-210–deficient cells (Supplemental Figure 
9). The GMAP-190 variant lacking the amino-terminal tethering motifs was reduced in its ability to 
rescue, consistent with the notion that the function of  the full-length GMAP-210 protein as a vesicle 
Figure 7. Golgi anchoring of IFT20 
in odontochondrodysplasia 
(ODCD). Wide-field microscopy 
of control and patient fibroblasts 
costained with antibodies direct-
ed against the cis-Golgi proteins 
GM130 and ZFPL1, as well as anti-
bodies directed against IFT20. 
Scale bar: 10 μm.
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tether is also important for Golgi organization. Putting results together, we reasoned that GMAP-210 is 
a nonredundant structural component of  the Golgi apparatus in humans, and even minimal quantities 
of  ODCD-associated GMAP variants are sufficient to rescue structural abnormalities. The phenotype 
of  ODCD, therefore, appears primarily due to reduced abundance of  the GMAP-210 protein.
An IFT20 Golgi pool is maintained by GMAP variants in ODCD. In addition to acting as a vesicle tether, 
GMAP-210 physically interacts with IFT20, which has recently been described as an essential regulator 
of  normal skeletal development (5, 30). Furthermore, IFT20 is dispersed and degraded when GMAP-210 
Figure 8. Normal global secretory traffic but defective glycan processing by the Golgi apparatus in odontochondrodysplasia (ODCD). (A) Pulse-
chase analysis of protein secretion of control and patient fibroblasts. Cells were starved for 1 hour in methionine- and cysteine-free medium and 
pulsed for 20 minutes with fresh starvation medium containing 50 μCi/ml [35S]methionine and [35S]cysteine protein labeling mix. Cells were chased 
in medium containing unlabeled methionine and cysteine for 0, 30, or 60 minutes and lysed. Radiolabeled cellular (cells) and secreted (medium) 
proteins, which were precipitated by trichloroacetic acid, were subjected to sodium dodecyl sulfate polyacrylamide gel electrophoresis and visualized 
by phosphor-imaging. (B) Ratio of secreted/total proteins at the indicated time points. Data represent mean ± SEM from 4 independent experiments 
(1-way ANOVA with Dunnett’s multiple comparisons test); **P < 0.01. (C) Pro-collagen, type 1, α-1 (pro-COL1A) concentration in conditioned media of 
primary fibroblasts determined by enzyme-linked immunosorbent assay. Data represent mean ± SD of quadruplicates (1-way ANOVA with Dunnett’s 
multiple comparisons test); **P < 0.01, ***P < 0.001. (D) Western blot analyses of LAMP1 and LAMP2 protein species in whole-cell lysates of patient 
and control fibroblasts. Hypo-glycosylated LAMP1 and LAMP2 proteins in achondrogenesis 1A (ACG1A) and ODCD run at a lower molecular weight 
range than in controls. (E) Western blot of secreted decorin (DCN) in conditioned supernatants of primary fibroblasts. High-molecular weight species, 
corresponding to glycanated DCN, include both slower and faster migrating forms in ACG1A and ODCD; different abundance of the core protein indi-
cates a secretory defect. Ponceau S staining of the membrane was used to assess the relative amount of precipitated and transferred total protein.
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is absent (5). In ciliated cells, IFT20 is a component of  the intraflagellar transport complex B (IFT-B) and 
the only known adapter mediating protein export from the Golgi apparatus to the primary cilium (5). 
However, costaining with acetylated tubulin revealed normal cilia and no difference in the ciliary signal 
of  IFT20 in serum-deprived fibroblast from controls, ACG1A, and ODCD (Supplemental Figure 10 and 
Supplemental Figure 11).
A recent report has described that IFT20 also regulates the nucleation of  Golgi-derived microtu-
bules, thereby promoting ribbon formation and polarized secretion in human chondrosarcoma cells 
(31). Therefore, we next focused on possible nonciliary roles of  IFT20 and found no protein at the 
Golgi apparatus in GMAP-210–deficient ACG1A cells using immunofluorescence microscopy (Figure 
7). In contrast, residual Golgi staining was detected in all ODCD cases, indicating that trace amounts 
of  GMAP protein variants are sufficient to target some IFT20 to the Golgi apparatus, with the amount 
correlating to the amount of  GMAP present in each case (Figure 7). Both exogenous full-length 
GMAP-210 and shorter GMAP variants lacking exons 4 or 9 restored IFT20 Golgi anchoring when 
overexpressed in ACG1A patient–derived cells (Supplemental Figure 12), consistent with the IFT20 
binding site lying outside of  these regions of  the protein (Figure 4A) (5).
The ability of  individual GMAP splice variants to bind to IFT20 in cells was further tested by induc-
ibly targeting the variants to mitochondria (32) and assessing the binding of  IFT20 to relocated GMAP 
by immunofluorescence microscopy (Supplemental Figure 13A) (8). As shown in Supplemental Figure 
13B, IFT20 was cotranslocated to mitochondria by GMAP-207 (encoded by TRIP11-ΔEx9), GMAP-200 
(encoded by TRIP11-ΔEx4), and GMAP-190 (encoded by TRIP11-ΔEx9short), demonstrating that they all 
contain a functional IFT20 binding site (5). We propose that complete loss of  IFT20 from the Golgi appa-
ratus in ACG1A contributes to the more severe cellular phenotype compared with ODCD, where residual 
IFT20 is present at the Golgi.
ODCD-associated GMAP variants sustain bulk secretory traffic in fibroblasts but are defective in glycan processing at 
the Golgi. It has been shown that GMAP-210 selectively interacts with transport vesicles via its ALPS motif  
and a second amino-terminal tethering motif  (21, 33). Subsequent interaction of  RAB2 mediates vesicle 
processing at the cis-Golgi in human cells (20). Using the mitochondrial rerouting assay, we analyzed vesicle 
capture by the GMAP variants in vivo (32). As observed previously for the full-length protein (8, 20), the 
Golgi-resident enzyme GalNAc-T2 accumulated at GMAP-positive mitochondria in the case of  the ODCD 
variants, indicating capture of  Golgi-derived vesicles (Supplemental Figure 14A). The only variant unable 
to capture GalNAc-T2–containing vesicles was GMAP-190 (encoded by TRIP11-ΔEx9short) because of  its 
missing amino-terminal tethering motifs. Thus, ODCD-associated GMAP splice variants are competent 
to tether transport vesicles to the cis-Golgi, as well to bind IFT20 (Supplemental Figure 14B). This again 
supports the notion that the ODCD phenotype arises from reduced protein abundance, as opposed to any 
inherent loss of  functionality of  variant GMAP proteins.
Since vesicle tethering is required for vesicular transport in the cell, we wondered whether the reduced 
abundance of  GMAP proteins in ODCD would impact on secretory trafficking, all the more so as a 
reduced capacity to locate IFT20 at the Golgi may also have an influence on Golgi function (30, 31). 
Therefore, total protein secretion by primary fibroblasts was measured as described (Figure 8A) (34). The 
cellular capacity to export nascent proteins into extracellular space correlated with the amount of  GMAP 
present at the Golgi. Compared with WT controls, the secretory output of  ACG1A fibroblasts was reduced 
to approximately 50% at all time points (Figure 8B). In contrast, bulk secretion was normal in ODCD fibro-
blasts, which contain residual amounts of  GMAP variants (Figure 8, A and B).
However, the remaining GMAP function in ODCD was not sufficient to ensure normal transport of  
all cargoes, as the levels of  procollagen, type 1, α-1 (pro-COL1A1) secreted by patient-derived fibroblasts 
were reduced compared with controls but were still significantly higher than in ACG1A (Figure 8C). In 
accordance with residual golgin function in ODCD, pro-COL1A1 secretion correlated positively with the 
amount of  GMAP/IFT20 complex at the Golgi; this may also endorse a role of  IFT20 for the trafficking 
of  specific substrates (Figure 8C) (30, 31).
To further assess Golgi functionality in the patient fibroblasts, glycosylation of  the lysosomal membrane 
proteins LAMP1 and LAMP2 was analyzed. Their glycosylation is dependent upon efficient intra-Golgi 
trafficking of  processing enzymes and serves as a sensitive readout of  Golgi functionality (35). As shown 
in Figure 8D, there was impairment of  LAMP1 and LAMP2 glycosylation in all patient-derived fibroblasts, 
as indicated by their lower apparent molecular weight upon SDS-PAGE. A severe glycosylation defect was 
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also observed for secreted decorin, which serves as a protein backbone for chondroitin and dermatan sulfate 
chains in the extracellular matrix (ECM). Decorin has diverse functions that depend on the length of  the 
attached glycosaminoglycan (GAG) chains, including the assembly of  collagen type I fibrils and the release 
of  cytokines (36, 37). Similar to aberrant LAMP protein mobility, the pattern of  high-molecular weight spe-
cies representing glycanated decorin differed greatly between controls and patients. However, these changes 
were more variable, with both larger and smaller glycanated forms detected in TRIP11-mutant cells (Fig-
ure 8E). Furthermore, the ratio of  glycanated decorin to core protein at approximately 40 kDa was differ-
ent from controls but not consistently changed in patients, with particular variances in the abundance of  
high-mobility forms among ODCD cases (Figure 8E). This is also the result of  reduced nonglycanated core 
protein at 40 kDa in ACG1A and severe ODCD, matching the findings for secreted pro-COL1A1 (Figure 
8D) and supporting the notion that impaired protein trafficking of  specific substrates (6) and their altered 
posttranslational modification may contribute independently to the pathogenesis and severity of  TRIP11- 
related disorders. We therefore conclude that, in both ACG1A and ODCD, Golgi functionality is severely 
impaired and disturbs secretion and posttranslational processing of  specific ECM components, but only in 
ACG1A is impairment strong enough to manifest as reduced secretory traffic of  global cargo.
Bulk ECM secretion is disrupted in TRIP11-mutant chondrogenic cells. To investigate the impact of  TRIP11 
mutations on human skeletal development, we then transdifferentiated primary dermal fibroblasts into 
mature chondrocytes (24). When cultured on an aggrecan-coated surface, fibroblasts can be induced by 
conditioned media to undergo a continuous differentiation process toward a chondrocyte lineage (FDC) 
(24, 38). The chondrocyte differentiation state at different days corresponds to that of  the distinct histologi-
cal zones in the growth plate (39). Proliferating FDCs form 3-dimensional chondrogenic nodules consisting 
of  secretory cells surrounded by cartilage matrix, which grow up to a size of  several hundred micrometers 
(Figure 9, A–C) and can be specifically stained by the cartilage proteoglycan dye Alcian blue (Figure 9D) 
(40). Total ECM synthesis, as quantified by Alcian blue extraction of  FDC cultures, increases with pro-
gressing FDC differentiation stage and peaks at day 7 in WT cells (Figure 9E). In TRIP11-mutant cells, the 
total number and the mean size of  chondrogenic nodules were significantly reduced (Figure 9, A and B), 
indicating that the production of  bulk glycosylated proteoglycans by FDCs was disrupted. Unexpectedly, 
no significant difference was observed between ACG1A and ODCD (Figure 9E), in contrast to a normal 
global secretory capacity of  the latter in fibroblasts (Figure 8B). Based on conditional Trip11-KO mice, it 
was recently proposed that GMAP-210 deficiency in chondrocytes only impairs the secretion of  selected 
ECM components that are retained intracellularly (6). Our results indicate a profound secretory defect of  
TRIP11-mutant chondrogenic cells for ECM proteoglycans, which is not improved by the hypomorphic 
GMAP variants in ODCD. We therefore questioned whether the severe impact of  GMAP-210 dysfunction 
on human chondrocytes was directly due to a rate-limiting trafficking defect of  highly secretory cells (1, 6).
Hypertrophic chondrocyte differentiation is impaired in ACG1A and ODCD. In the few published histological 
studies (3, 41, 42), growth plates of  ACG1A fetuses show a reduction of  total epiphyseal cartilage and 
the absence of  columnar chondrocytes in the prehypertrophic and hypertrophic zones (42). Accordingly, 
collagen, type X, α-1 (COL10A1), a specific cargo secreted by terminal hypertrophic chondrocytes at high 
levels, was not detectable in the ECM (42). In line with published data, no columnar chondrocytes were 
found in the femoral growth plate of  case A5 (Supplemental Figure 15A). However, overall cell numbers 
were not reduced as the reserve and proliferative zones were expanded and hypercellularity was observed 
(Supplemental Figure 15, A and B).
Addressing the possibility that reduced ECM synthesis by TRIP11-mutant human FDCs was nonethe-
less due to lower cell numbers, we found that proliferation was not impaired during chondrogenesis (Sup-
plemental Figure 15C). Moreover, cell viability remained in the same range at all stages of  induced differ-
entiation. Contrary to previous observations in constitutive Trip11-mutant mice (1), no evidence was found 
that human GMAP-210 deficiency causes ER swelling (Supplemental Figure 8) and triggers apoptosis (Sup-
plemental Figure 15D). We therefore hypothesized that GMAP dysfunction disrupts endochondral ossifi-
cation, and we studied chondrocyte differentiation markers in FDCs. Late-stage FDCs display the proper-
ties of  prehypertrophic and terminal hypertrophic chondrocytes, characterized by a strong upregulation of  
matrix metalloprotease 13 (MMP13) and COL10A1 (Figure 9, F and G) at days 5–7. In both ACG1A- and 
ODCD-derived cells, the terminal hypertrophic differentiation state was never attained, as indicated by per-
sistently low levels of  COL10A1 mRNA and protein (Figures 9F and Supplemental Figure 15E). Further-
more, whereas pro-MMP13 was induced in late-stage control FDCs, levels in TRIP11-mutant cells remained 
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as low as in nondifferentiated fibroblasts (Figure 9G and Supplemental Figure 15F). Conversely, analysis of  
pro-COL1A1 in mature chondrogenic cells revealed that the secretory trafficking of  some cargoes was still 
significantly more efficient in ODCD than in ACG1A (Figure 9H). COL1A1 is ubiquitously expressed and 
not restricted to hypertrophic chondrocytes as the other 2 studied markers. We conclude that low levels of  
COL10A1 and pro-MMP13 in ODCD do not solely reflect a rate-limiting trafficking defect of  chondrocytes, 
but are also the result of  failed induction of  terminal chondrogenic differentiation. These findings support 
the notion that GMAP-210 is a critical regulator of  hypertrophic chondrocyte differentiation and that muta-
tions in TRIP11 cause a common chondrocyte maturation defect in ACG1A and ODCD (Figure 10).
Discussion
By follow-up of  published and additional patients, we studied the natural history in the largest series 
of  ODCD cases to date, to our knowledge. Clinical-radiographic overlap with ACG1A and a recessive 
inheritance pattern were instrumental for the identification of  TRIP11 as the causative gene in ODCD. 
Our clinical observations add 2 important aspects to the description of  ODCD (10–12): first, there is 
Figure 9. Impaired synthesis of extracellular matrix (ECM) components and disrupted chondrogenic differentiation of TRIP11-mutant cells. (A) 
Number of chondrogenic nodules at day 7 of transdifferentiation of fibroblasts (fibroblast-induced chondrocytes, FDC) in controls and patients. 
(B) Size of the chondrogenic nodules at day 7, as exemplified for case 6 by inverse microscopy of live cells in (C). Scale bar: 100 μm. (D) Alcian blue 
staining of transdifferentiated patient-derived primary and matched control FDC cultures at days 1–7 of chondrogenic differentiation demon-
strates reduced matrix production in patient cells. Scale bars: 150 μm. (E) Quantification of total glycosaminoglycan/proteoglycan content in FDCs; 
data points represent the mean of triplicate values (n = 3); error bars indicate ± SD. (F and G) Quantitative ELISA shows that secreted markers of 
terminal differentiation, COL10A1 and pro-MMP13, are significantly reduced in supernatants of patient-derived cultures at late time points of the 
transdifferentiation protocol. CTL, controls 1 and 2; ODCD, odontochondrodysplasia cases 3, 6, and 10; ACG1A, achondrogenesis 1A cases A1 and A2. 
Data points represent the mean of quadruplicate values (n = 4); error bars indicate ± SD. (H) Quantitative ELISA of pro-collagen, type 1, α-1 (pro-CO-
L1A1) in conditioned FDC supernatants. Data represent mean ± SD of quadruplicates (2-way ANOVA with Bonferroni’s post hoc test);  *P ≤ 0.05, **P 
< 0.01, ***P < 0.001, ****P < 0.0001.
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considerable clinical variability in TRIP11-related disorders, with early lethality and milder postnatal 
phenotypes occurring within the same family, and second, there are extraskeletal disease manifesta-
tions in ODCD that implicate GMAP-210 in human renal and cerebral development (15). The role of  
GMAP-210 in organogenesis and tissue homeostasis may, thus, be wider than assumed on the basis of  
Figure 10. The function of the GMAP/IFT20 complex in development and disease. (A) Functioning as a membrane tether, 
GMAP-210 anchors IFT20 to the cis-Golgi apparatus. IFT20 is involved in cargo sorting to the cilium (e.g., polycystin-2). 
Golgi organization is essential for proper secretory transport and posttranslational protein modification. (B) Odontochon-
drodysplasia-associated (ODCD-associated) GMAP hypomorphs and natural splice variants partially maintain the struc-
ture of the Golgi apparatus. In achondrogenesis 1A (ACG1A), GMAPs are fully lost. Golgi structure is disrupted, and bulk 
secretory traffic is reduced. Aberrant posttranslational protein modification disrupts chondrocyte differentiation in both 
ODCD and ACG1A. Impaired synthesis and secretion of extracellular matrix (ECM) proteoglycans cause skeletal disease.
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current Trip11-KO models. These models all bear the disadvantage of  perinatal lethality, precluding the 
recognition and analysis of  later-onset phenotypes (1, 5, 6). Comprehensive characterization of  indi-
vidual mutations revealed that all ODCD patients, in addition to a TRIP11-null allele, carry compound 
heterozygous splice variants, which are translated into low-abundance GMAP proteins. Our findings 
establish that ODCD is genetically homogeneous and that hypomorphic mutations of  TRIP11 are the 
genetic basis for a range of  ODCD phenotypes.
Is there hence a consistent genotype-phenotype correlation in TRIP11-related disorders? Our results 
support that a complete loss of  TRIP11 fatally disrupts skeletal development and invariably causes ear-
ly embryonic lethality in ACG1A, whereas recurrent splice mutations are associated with a milder but 
variable spectrum of  postnatal clinical phenotypes. At the cellular level, phenotypic severity is clearly cor-
related with a reduction of  functional GMAP proteins at the Golgi apparatus. However, the very same 
hypomorphic mutations may lead to both early lethal disease and milder ODCD. A radiographic diag-
nosis of  ACG1A and ODCD in different children originating from the same parents may be primarily 
due to variable penetrance of  TRIP11 missplicing between individuals, resulting in constitutively different 
amounts of  residual GMAP protein. Thus, our results make the prediction of  clinical outcome solely based 
on genotype difficult in genetic counselling and clinical care. Although our functional data corroborate 
that ODCD is the milder allelic form of  ACG1A, clinical variability associated with hypomorphic TRIP11 
mutations is too high for a reliable genotype-phenotype correlation, at present.
How do hypomorphic TRIP11 alleles rescue the embryonic lethality? Notably, a drastic reduction of  
full-length GMAP-210 protein was evident in both ACG1A and ODCD, leaving only trace amounts of  
altered GMAP proteins in the latter; a milder clinical phenotype may, thus, still have extrinsic reasons, as 
well. However, by comparing the cellular phenotypes of  ACG1A and ODCD in primary cells, we identi-
fied surprisingly clear-cut differences that were directly attributable to preserved golgin functions of  residual 
GMAP proteins: first, ODCD-associated splice mutations were permissive for the generation of  low-abun-
dant proteins, while all mRNA isoforms of  TRIP11 were effectively eliminated by NMD in ACG1A. Golgi 
morphology and ultrastructure was much less disordered in ODCD than in ACG1A, where the organelle 
was compacted, fragmented, and dispersed into irregular vesicular profiles. Second, only in ODCD, there 
was a sustained recruitment of  IFT20 to the Golgi apparatus, which again was directly dependent on resid-
ual GMAP quantity in patient cells. All ODCD-associated and natural GMAP splice variants retained an 
IFT20 binding site and rescued the dispersal of  the IFT20 Golgi pool in GMAP-210–negative cells. IFT20 
may directly be involved in the ER-to-Golgi transport of  specific cargoes (30). Recent data indicates that 
IFT20 regulates the nucleation of  Golgi-derived microtubules in nonciliated cells by physical interaction 
with the GM130–A-kinase anchor protein 450 (GM130-AKAP450) complex (31). The formation of  a 
microtubule network emanating from the cis-Golgi membrane by IFT20 was shown to promote ribbon for-
mation and to increase the efficiency of  anterograde transport through the Golgi complex (31). Sustained 
Golgi targeting of  IFT20 in ODCD may, therefore, attenuate the structural and functional Golgi defect 
caused by GMAP-210 deficiency. The importance of  a preserved GMAP/IFT20 complex for a milder 
cellular and clinical phenotype of  ODCD was strongly supported by a third essential difference to ACG1A 
detected in patient-derived cells: whereas a strong reduction of  total membrane trafficking was observed in 
ACG1A, the global secretory capacity of  the Golgi was normal in ODCD, at least in primary fibroblasts.
Taken together, minimal amounts of  functional GMAP are sufficient to restore Golgi function to a 
degree that permits pre- and postnatal survival in ODCD. Rescue of  the structural and functional Golgi 
defects likely depends on vesicle tethering but may also depend on the recruitment of  IFT20 by GMAP to 
the cis-Golgi. In turn, complete loss of  the GMAP-210/IFT20 complex in ACG1A leads to early embryon-
ic lethality due to a global trafficking defect of  the Golgi apparatus (Figure 10).
How do developmental anomalies emerge in TRIP11-related disorders? Our clinical and functional 
data suggest that independent mechanisms may contribute to organ-specific disease manifestations in 
ACG1A and ODCD: in the skeleton, the structural and functional defects of  the Golgi apparatus disrupt 
glycan processing with a pronounced and early impact on chondrocyte differentiation. A block in cellular 
differentiation impairs the evolution of  hypertrophic chondrocytes, which synthesize key cartilage matrix 
proteins in the growth plate, including COL10A1. A more severe skeletal phenotype in ACG1A may be 
due to the global reduction of  secretory traffic. The etiology of  the differentiation defect remains currently 
unclear, but we hypothesize that aberrant posttranslational processing and secretion of  a limited number 
of  secreted developmental regulators with key importance for early chondrogenesis, like decorin (36, 37), 
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are major mechanism in the skeleton (43). This view is supported by the fact that aberrant posttranslational 
processing of  selected glycans causes ACG1B, a lethal skeletal dysplasia with a highly similar skeletal phe-
notype to ACG1A (44).
Our studies did not provide support for a cilium-dependent pathogenesis in TRIP11-related disorders, 
as cilia in GMAP-210–deficient fibroblasts had normal length and exhibited no structural abnormalities. 
Furthermore, ciliary targeting of  IFT20 itself  was normal in ODCD and ACG1A, in spite of  its partial, 
or complete, dispersal from the Golgi. However, known substrates of  GMAP-210/IFT20-mediated ciliary 
export, like polystcystin-2 (5) and fibrocystin (45), are not expressed in fibroblasts or chondrocytes, so we 
were unable to assess a potential functional defect of  primary cilia in TRIP11-mutant human cells. There-
fore, we cannot exclude that a ciliary export defect of  other currently unknown proteins contributes to the 
developmental phenotype.
None withstanding, radiographic features of  ACG1A and ODCD are characteristic of  skeletal ciliop-
athies — in particular, the combination of  thoracic dystrophy, brachydactyly with cone-shaped epiphyses, 
and a trident pelvis (14). The pattern of  extraskeletal disease manifestations in ODCD with variable dental, 
renal, and cerebral anomalies is also suggestive of  an underlying cilium-based pathogenesis. The same 
organs are affected in an overlapping condition known as cranioectodermal dysplasia, or Sensenbrenner 
syndrome, which is caused by hypomorphic mutations of  IFT122, another component of  the IFT-B com-
plex (46). Impaired release of  IFT20 from the Golgi and subsequent disturbance of  ciliary export was 
recently implicated as an underlying disease mechanism in another ciliopathy with skeletal, renal, and 
retinal involvement (47). It is therefore tempting to speculate that at least the late-onset cystic renal degen-
eration observed in ODCD may be primarily due to impaired ciliary transport functions of  IFT20, as the 
conditional deletion of  Ift20 during renal development causes polycystic kidney disease and aberrant WNT 
signaling in neonatal mice (48). A similar significance of  IFT20 for the other extraskeletal manifestations in 
ODCD remains to be investigated. We propose that a genuine disease model of  ODCD will be a straight-
forward way to unravel the organ-specific tasks of  GMAP-210 in development.
In conclusion, we demonstrate here that biallelic mutations of  TRIP11 cause a spectrum of  skeletal 
phenotypes whose severity is primarily based on impaired secretory trafficking and aberrant glycan process-
ing by the Golgi apparatus. Our results support a critical nonciliary role of  IFT20 for Golgi organization 
and membrane trafficking in the growth plate. Further elucidation of  the skeletal and extraskeletal disease 
manifestations of  TRIP11-related disorders will allow a dissection of  the multiple functions of  the GMAP-
210/IFT20 complex in vesicular transport, protein modification, and ciliary transport.
Methods
Patients and mutation analysis. DNA was obtained by standard extraction procedures (Qiagen). For genomic 
analysis and mutation detection, exons including intron-exon boundaries of  TRIP11 were amplified by 
PCR using standard protocols as described (29), primers are listed in Supplemental Table 2. Array CGH 
analysis was carried out using 180K oligonucleotide arrays, as described previously, on an Agilent platform 
(49). Image quantification, array quality control, and aberration detection were performed by DNA analyt-
ics software packages (CytoGenomics) according to the manufacturer’s instructions (Agilent).
Cell culture, treatment, and transfection. COS7 and HeLaM (ATCC) cells were grown at 37°C and 5% 
CO2 in DMEM supplemented with 10% (vol/vol) FBS, 1 mM L-glutamine, 1% nonessential amino acids 
(NEAA), and 1% penicillin-streptomycin mix (all from Invitrogen). Human dermal fibroblasts from 
patients and healthy controls were obtained from skin biopsies and expanded to passage 3 (p3). Fibroblasts 
were maintained in 90% DMEM (4.5 g/l glucose, Invitrogen), 10% FBS (from PAA Laboratories), 0.1 mM 
NEAA, 100 U/ml penicillin, and 100 μg/ml streptomycin (all from Invitrogen) in humidified atmosphere, 
37°C, and 5% CO2. Monocilia were induced in subconfluent cultures seeded on glass coverslips by serum 
starvation for 48–72 hours as described (50). Secreted decorin was collected from confluent fibroblasts 
in 6-well plates; medium was changed to serum-free DMEM containing all other supplements 48 hours 
prior to collection (37). For FDC transdifferentiation, matched p5 cell populations were seeded on bovine 
aggrecan–coated 24-well plates (MilliporeSigma) at 400,000 cells per well in FDC differentiation medi-
um: DMEM/F12 (Invitrogen), 10% FBS, antibiotic/antimycotic (Invitrogen), NEAA, 50 μg/ml L-ascor-
bic acid-2-phosphate (MilliporeSigma), 1% insulin/transferrin/selenite (Invitrogen), and 10 ng/ml TGFβ3 
(R&D Systems) (24). Differentiation medium was changed every 2 days, and samples for protein and RNA 
analyses were obtained at days 1, 3, 5, and 7 and compared with samples obtained prior to plating (day 0). 
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HEK293T cells were transfected with expression plasmids using polyethylenimine MW25000 (Polyscienc-
es). Cell viability/proliferation was determined using the WST-1 reagent as described (Roche Diagnostics) 
(51). Phenotypic rescue experiments were conducted by transfection of  case A2 fibroblasts with expression 
vectors containing C-terminally myc-tagged GMAP-210 variants using FuGene HD according to the man-
ufacturer’s instructions (Promega) or by electroporation, as described elsewhere (20).
Plasmids, reagents, and antibodies. The ORF of  full-length TRIP11 (Ensembl: ENST00000267622.8, Gen-
Bank: NM_004239.3) was cloned into the pcDNA5/FRT/TO vector (Thermo Fisher Scientific) carrying 
a carboxy-terminal myc-tag (20, 26). To obtain the TRIP11-ΔEx4 and the TRIP11-ΔEx9short variants, the 
5′-end of  full-length TRIP11-pCDNA5/FRT/TO was replaced with fragments generated by amplifying the 
respective region from patient cDNA by PCR and directional insertion of  the DNA fragments via KpnI 
and PacI sites; an internal KpnI restriction site in the WT TRIP11 construct was eliminated by site-directed 
mutagenesis before directional cloning. Primer sequences are listed in Supplemental Table 3. To obtain 
the TRIP11-ΔEx9 variant containing a complete 5′-end, a digested DNA amplicon of  exons 1–5 from WT 
cDNA replaced the 5′-end of  the TRIP11-ΔEx9short variant. All generated plasmids were verified by com-
plete bidirectional sequence analysis using primers listed in Supplemental Table 4.
The following antibodies were used: rabbit anti-TRIP11 (HPA002570, MilliporeSigma), mouse anti-
TRIP11 (E-2, Santa Cruz Biotechnology Inc.), mouse anti-GAPDH (G-9, Santa Cruz Biotechnology 
Inc.), rabbit anti-GM130 (anti-N73pep) (52), mouse anti-GM130 (clone 35, BD Biosciences), rabbit anti-
IFT20 (13615-1-AP, Proteintech), sheep anti-TGN46 (provided by Sreenivasan Ponnambalam, University 
of  Leeds, Leeds, United Kingdom), sheep anti-ZFPL1 (53), mouse anti–GalNAc-T2 (provided by Hen-
rik Clausen, University of  Copenhagen, Denmark), mouse anti-myc (9B11, Cell Signaling Technology), 
goat anti-Myc (ab9132, Abcam), rabbit anti-GORAB (generated in house), sheep anti–golgin-84 (54), 
rabbit anti-LAMP1 (D2D11, Cell Signaling Technology), mouse anti-LAMP2 (H4B4, Developmental 
Studies Hybridoma Bank, University of  Iowa, Iowa City, Iowa, USA), anti-decorin (14667, Proteintech), 
mouse anti-acetylated tubulin (clone 6-11B-1, MilliporeSigma), and mouse anti–α-tubulin (T9026, Milli-
poreSigma). Anti-MMP13 (MAB13424 and AB8114, MilliporeSigma; dilution 1:1,000), anti-COL10A1 
(LS-C346132, LifeSpan Biosciences, dilution 1:1,000); and Alexa 488-, 546-, 594-, and 647-conjugated 
secondary antibodies were from Molecular Probes (Thermo Fisher Scientific). Horseradish peroxidase–
conjugated secondary antibodies were from MilliporeSigma.
RNA extraction and RT-PCR. Total RNA from fibroblasts and cell lines was extracted with Trizol (Invit-
rogen), followed by DNaseI treatment (Roche Diagnostics) and column purification (Qiagen); cDNA was 
synthesized from 1 μg total RNA with Superscript III reverse transcriptase (Invitrogen), random hexanu-
cleotides (MilliporeSigma), and oligo dT16 primers as described (29). Quantitative PCR (qPCR) was per-
formed on a CFX384Touch Real-Time PCR System (Bio-Rad). 2–ΔΔCt relative quantification, PCR efficien-
cy correction, and multiple reference gene normalization were calculated with qBase (29). Oligonucleotides 
were designed using the Primer 3 software (http://primer3.ut.ee/) and are listed in Supplemental Table 5.
Immunoblotting. Fibroblasts were lysed using HMNT lysis buffer (20 mM HEPES-KOH [pH 7.4], 5 
mM MgCl2, 0.1 M NaCl, 0.5% [wt/vol] Triton X-100) supplemented with protease inhibitor cocktail (Cal-
biochem). Total proteins from conditioned supernatants were precipitated by trichloroacetic acid (TCA) as 
described (37). Cell lysates (30 μg) were separated by electrophoresis in SDS-PAGE. Gels were then trans-
ferred onto a PVDF membrane (Amersham Hybond P 0.45, GE Healthcare) using a wet transfer system. 
The efficiency of  transfer was assessed by Ponceau S stain (MilliporeSigma). Membranes were blocked by 
incubation in PBST buffer (PBS with 0.1% Tween-20) supplemented with 5% skimmed milk for 1 hour at 
room temperature (RT) and incubated with primary antibody solution (5% skimmed milk in PBST) over-
night at 4°C. Membranes were washed 3 times in PBST buffer for 5 minutes each at RT (subsequent steps at 
RT) and incubated with secondary antibody solution (5% skimmed milk in PBST) for 1 hour. Membranes 
were washed 3 times in PBST buffer for 5 minutes and once in PBS for 5 minutes. The immunoreaction was 
detected with SuperSignal West Pico ECL chemiluminescent substrate (Thermo Fisher Scientific) using 
Bio-Rad Chemidoc MP Imager. Data were analyzed using Image Lab software (Bio-Rad). Analysis of  
molecular weight of  GMAP-210 variants was conducted using a dedicated molecular weight analysis tool 
in Image Lab software (Bio-Rad) by comparing bands with known protein standards.
Immunodetection of  proteins and histochemistry. Cells and supernatants were harvested 48–72 hours after 
transfection or at the indicated time points of  the FDC protocol; prior to protein extraction, cells were 
washed twice with PBS. Lysates were prepared by incubation in 1 ml lysis buffer (20 mM Tris-HCl [pH 8], 
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137 mM NaCl, 10% glycerol, 1 mM NaF, 1 mM Na3VO4, 0.1% NP-40) plus complete protease inhibitor 
(Roche Diagnostics) for 20 minutes on ice, followed by centrifugation at 14,000 g and at 4°C for 10 minutes. 
For the analysis of  secreted proteins, the medium was changed to serum-free Optimem I (Invitrogen), or 
serum-free DMEM containing all other supplements, 12–24 hours prior to collection. Pro-MMP13 (Quanti-
kine DM1300, R&D Systems), COL10A1 (MBS917063, MyBiosource), pro-COL1A1 (ab210966, Abcam), 
and active caspase-3 (Quantikine KM130, R&D Systems) were quantified in conditioned supernatants and 
cell extracts by chromogenic ELISA as described (55).
Total GAG/proteoglycan content in FDC cultures was measured by an Alcian blue extraction 
method (40). Cells were carefully washed twice with PBS and fixed in 100% methanol for 30 minutes at 
–20°C, rinsed with distilled water, and incubated overnight at RT with staining solution (0.5% Alcian 
blue 8 GS [Carl Roth] in 1 N HCl). After extensive washing with distilled water, the dye was extracted 
with 500 μl of  6 M guanidine HCl in distilled water for 6 hours at RT. The optical density of  the extract 
was determined by spectrophotometry at 630 nm (Dynatech). GAG values were normalized to cell 
numbers using WST-1, as described (51).
Fluorescence microscopy. Fibroblasts were seeded on glass coverslips and grown till 90% confluency. Cells 
were washed twice with PBS and fixed with 3% (wt/vol) paraformaldehyde (PFA) in PBS for 25 minutes 
at RT. Cells were then washed with PBS, and excess PFA was quenched with glycine. Cells were permea-
bilized by 4-minute incubation in 0.1% (wt/vol) Triton X-100 in PBS. Cells were incubated with primary 
antibody diluted in PBS for 1 hour at RT, washed 3 times with PBS, and then incubated for 1 hour with sec-
ondary antibody diluted in PBS, sometimes together with 100 ng/ml Hoechst 33342 dye (Thermo Fisher 
Scientific) to stain DNA. Following another 3 washes with PBS and 2 in ddH20, coverslips were mounted in 
Mowiol 4-88. Images were acquired using an Olympus BX60 upright microscope equipped with a Micro-
Max cooled, slow-scan CCD camera (Princeton Instruments) driven by Metaview software (University 
Imaging Corporation). Images were processed using ImageJ software (NIH).
Electron microscopy. Cells were grown on 10-cm dishes until they reached 80% confluency. The samples 
were fixed with 4% formaldehyde + 2.5% glutaraldehyde in 0.1 M HEPES buffer (pH 7.2), and cells were 
scraped and centrifuged at 5,200 g for 10 minutes. Cells were post-fixed with 1% osmium tetroxide + 1.5% 
potassium ferrocyanide in 0.1 M cacodylate buffer (pH 7.2) for 1 hour and in 1% uranyl acetate in water 
for 1 hour. The samples were dehydrated in ethanol series infiltrated with low-viscosity resin (TAAB) and 
polymerized for 24 hours at 60°C. Sections of  70 nm were cut with an Ultracut ultramicrotome (Reichert) 
and observed with a FEI Tecnai 12 Biotwin microscope at 100 kV accelerating voltage. Images were taken 
with a Gatan Orius SC1000 CCD camera. Quantification of  cells with large vesicular profiles, defined as 
peri-Golgi circular profiles with a diameter of  >100 nm, were conducted manually in a blinded manner.
Mitochondrial relocation assay. The mitochondrial relocation assay was performed as previously 
described (20). Briefly, HeLaM cells were cotransfected with plasmids carrying TRIP11-mycFKBP variants 
and mito-FRB plasmid (a gift from Stephen Royle, University of  Warwick, Warwick, United Kingdom) 
using FuGene HD (Promega). The following day, HeLaM cells were treated with 2.5 μg/ml nocodazole 
(MilliporeSigma) for 2 hours, followed by addition of  1 μM rapamycin (Calbiochem) for 3 hours to induce 
targeting of  TRIP11-mycFKBP onto mitochondrial outer membranes. Cells were fixed and processed for 
immunocytochemistry as described above.
Pulse-chase analysis of  protein secretion. Analysis of  protein secretion was performed using a pulse-chase 
approach as described previously (34). Cells were seeded onto 3.5-cm dishes and grown until they reached 
95% confluency. Cells were starved for 1 hour in methionine- and cysteine-free DMEM (Invitrogen) sup-
plemented with 10% (vol/vol) FBS and 1 mM L-glutamine and pulsed for 20 minutes with fresh starvation 
medium containing 25 mCi/ml [35S]Met and [35S]Cys protein labeling mix (PerkinElmer). After washing 
with PBS, cells were incubated in chase medium (DMEM, 10 mM HEPES [pH 7.4], 1 mM methionine, 1 
mM cysteine, 100 μg/ml bovine serum albumin) for 0, 30, or 60 min. Proteins secreted to the medium were 
precipitated using TCA, while cells were lysed using HMNT lysis buffer. Cells and medium fractions were 
subjected to SDS-PAGE; gels were fixed for 10 minutes in 20% (vol/vol) methanol and 10% (vol/vol) acetic 
acid and dried for 2 hours at 65°C using a gel dryer (Bio-Rad). Dried gels were exposed to phosphor-im-
aging plates and developed after 10 days using a fluorescent image analyzer (FLA 7000, Fujifilm). Signals 
from radiolabeled proteins were quantified using AIDA software (Elysia-raytest).
Statistics. Statistical analyses were conducted with use of  GraphPad Prism software (GraphPad Soft-
ware). D’Agostino-Pearson and Shapiro-Wilk tests were used for comparison of  the distribution of  data 
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with a Gaussian distribution. Depending on the result, a Mann-Whitney U test or 1- or 2-way ANOVA with 
Bonferroni’s correction for multiple comparisons was performed. The number of  cells with large vesicular 
profiles and the Golgi morphology classes in the rescue experiments of  Golgi compaction/fragmentation 
in case A2 fibroblasts were compared using a χ2 test. Amounts of  secreted proteins were compared using 
1-way ANOVA followed by Dunnett’s multiple comparisons test. Statistical significance cut-offs were set as 
follows: *P ≤ 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001.
Study approval. All individuals in our study were recruited by physician-initiated referral. The study was 
conducted in accordance with the Declaration of  Helsinki protocols and approved by the institutional ethics 
review board of  Freiburg University Hospital, Germany (Ethik-Kommission der Albert-Ludwigs-Universi-
tät Freiburg Nr. 349/13). Written informed consent for skin and tissue biopsies and molecular studies was 
obtained from the affected individuals and/or their legal guardians in accordance with current German law 
(GenDG). Control samples and primary cells were collected from ancestry-, sex-, and age-matched healthy 
individuals under the same criteria and regulations.
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